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Summary 
Locally recurrent rectal cancer remains a significant clinical challenge, with a poor prognosis. 
Curative resection remains the most important factor for survival but is associated with 
significant morbidity and technical challenges. Re-irradiation is as a therapeutic alternative 
and been shown to have a significant palliative effect but concerns exist around tolerances. 
We attempt to improve on this by using stereotactic approaches and report here on initial 
local control, toxicity and survival outcomes of our cohort.  
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Running title: SBRT re-irradiation for locally recurrent rectal cancer 
Abstract 
Background 
Stereotactic body radiotherapy (SBRT) has emerged as a potential therapeutic option for 
locally recurrent rectal cancer (LRRC) but contemporaneous clinical data is limited. We 
aimed to evaluate the local control, toxicity and survival outcomes in a cohort of patients 
previously treated with neoadjuvant pelvic radiotherapy for non-metastatic LRRC, now 
treated with SBRT. 
Methods 
Inoperable rectal cancer patients with ≤ 3 sites of pelvic recurrence and > 6 months since 
prior pelvic radiotherapy were identified from a prospective registry over 4 years. SBRT dose 
was 30Gy in 5 fractions, daily or alternate days, using cumulative organ at risk dose 
constraints. Primary outcome was local control (LC). Secondary outcomes were progression 
free survival (PFS), overall survival (OS), toxicity and patient reported Quality of Life scores 
(QoL) using EQ-VAS tool.  
Results 
30 patients (35 targets) were included. Median GTV size was 14.3cm3. 27/30 (90%) 
previously received 45-50.4Gy in 25/28 fractions, with 10% receiving an alternative 
prescription. All patients received the planned re-irradiation SBRT dose. The median FU was 
24.5 months (IQR 17.8 – 28.8). The 1-year LC was 84.9% (95% CI 70.6 – 99) and a 2-year 
LC was 69% (95% CI 51.8 – 91.9). The median PFS was 12.1 months (95% 8.6 – 17.66) and 
median OS was 28.3 months (95% CI 17.88 – 39.5 months). No patient experienced >G2 
acute toxicity and only 1 patient experienced late G3 toxicity. Patient reported QoL outcomes 
were improved at 3 months following SBRT (Δ EQ-VAS, +10 points, Wilcoxon signed rank, 
p=0.009). 
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Conclusion 
Our study demonstrates that, for small volume pelvic disease relapses from rectal cancer, re-
irradiation with 30Gy in 5 fractions is well tolerated and achieves an excellent balance 
between high local control rates with limited toxicity. 
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INTRODUCTION 
 
Locally recurrent rectal cancer is defined as recurrence of rectal cancer within the pelvis after 
previous surgical resection 1. Local recurrence rates remain approximately 10% and the 
majority of those that recur will have received neo adjuvant (chemo) radiotherapy as part of 
initial multimodality treatment 2–4.  Prognosis is poor with significant morbidity and poor 
quality of life  from pelvic pain, fistula, bleeding and faecal discharge 5. Untreated LRRC has 
a median survival of 6 months, improving with chemotherapy and/or radiation 12-16 months 
6
.  
 
Curative resection remains the most important factor for survival 6,7. However, surgery for 
LRRC is challenging because of altered anatomical planes and tissue fibrosis from previous 
radiotherapy and primary resection. Pelvic exenteration is associated with significant 
morbidity and not always feasible 8,9. There is also no clear consensus about which cases 
should go for resection.  
 
Re-irradiation is emerging as a therapeutic alternative and has been shown to have a 
significant palliative effect and favourable survival outcomes 6,10. Delivery is challenging 
because of concern tissues may have already received doses near the organ tolerance during 
primary treatment, particularly the small intestine.  Historically,  LRRC was treated with 
large volumes to ensure target coverage and planned conformally 11,12.  Doses were 
hyperfractionated (1.2Gy-1.5Gy) which had a sound radiobiological potential to reduce late 
effects. Further technical advances such as the use of IMRT 13 have been employed to reduce 
side effects. Proton beam therapy also has a dosimetric advantage, compared to photons, with 
pelvic bone marrow particularly spared in a recent series 14, although doses were again 
hyperfractionated. Stereotactic ablative radiotherapy (SBRT), which involves very accurate 
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delivery of a high radiation dose in a small number of fractions to a target with narrow 
margins 15,  can potentially increase the precision and reduce off target effects,   in re-
irradiation cases 16.  
The evidence base to date for the use of SBRT in re-irradiation in rectal cancer is limited with 
just three published cohorts, each less than 20 patients 10,17–19. The aim of this work is to 
evaluate the local control, toxicity and survival outcomes in a contemporaneous cohort of 
non-metastatic LRRC patients, treated with SBRT. 
 
METHODS 
Patient Selection 
Using a prospectively maintained database, patients treated with re-irradiation using SBRT 
for LRRC at XXXXX Hospitals and XXXX Cancer Centre between October 2015 and June 
2019 were identified. Patients were previously treated with (chemo) radiation to the pelvis for 
rectal cancer. Full restaging of both the local and distant disease (CT and/or MRI and/or PET 
imaging) was mandated prior to treatment. Patients were all discussed at a colorectal 
specialist multidisciplinary meeting for surgery and only inoperable patients, with less than 3 
metastases, who had a disease-free survival of at least 6 months, WHO performance status 0-
2 and greater than 6 months since previous radiotherapy were considered suitable for SBRT 
re-irradiation. Where the history, examination and imaging findings were in keeping with 
rectal cancer recurrence a repeat biopsy was not required. All patients consented to collection 
of data as part of enrolment in the SBRT treatment program 20, which had received ethical 
approval (XX-XXX). 
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Re-irradiation 
Patients were treated either using a linear accelerator SBRT platform with daily image guided 
verification with cone beam CT scan (n=16) or with the Accuray Cyberknife treatment 
system (n=14) using fiducial markers or bony landmarks for set up and intra-fraction motion 
management. 30Gy in 5 fractions with daily or alternate day fractionation over 7 -10 days 
were delivered. The locations of the pelvic recurrences were mapped using a previously 
published atlas 21. To allow equal comparison across the different initial fractionations the 
EQD2(α/β 3) for late responding tissues and EQD2(α/β 10), BED10 for tumours were calculated. 
 
The planning target volume was the gross tumour volume (GTV) as identified on MRI with a 
3mm margin in all directions. Organs at risk (OARs) delineated included small and large 
bowel, bladder, cauda-equina and sacral plexus/roots. Previous radiotherapy plans and dose 
volume histograms were reviewed for relevant dose metrics. Dose constraints to OARs 
overlapping target were prioritised (Supplementary Table  1), with maximum cumulative 
doses to small bowel and bladder of 98Gy3 EQD2 and 120Gy3 EQD2 respectively 22. For 
sacral nerve roots, where relevant, recovery of up to a third of previously received doses was 
assumed. Cumulative dose was calculated using a summation method where addition of the 
maximal point dose with the OAR from the planning data of the original plan is added to the 
maximal point dose within the corresponding OAR on the re-irradiation plan simulation. No 
patients received concurrent systemic therapy at the time of SBRT.  
 
Response and toxicity assessment and follow up 
Treatment response was evaluated according to the response evaluation criteria in solid 
tumours 23. Toxicity within the first 3 months after SBRT was considered acute and late if 
first occurring after this time point. Clinical and/or telephone assessments were performed at 
baseline, 1, 3 and 6 months following SBRT, then at 6 monthly intervals thereafter and 
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imaging at the same timepoints. Toxicity was recorded according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0). Quality of life 
was assessed using the EuroQol EQ-5D tool, which consists of the five level EQ-5D 
descriptive system and the EQ visual analogue scale (EQ VAS) 24. The latter patient reported 
outcome measure (PROM) measured on a continuous scale, where 100 signifies ‘best 
imaginable health’ and 0 ‘worst imaginable health’, on which patients provide a global 
assessment of their health.  
   
The primary outcome of interest was local control (LC), defined as recurrence or progression 
within the re-irradiation field. Secondary outcomes were time to first site of radiological 
progression (PFS), time to death (OS) and quality of life outcomes. Locoregional progression 
(LRP) was defined a disease progression outside the PTV but within the pelvis, distant 
progression as disease sites outside the pelvis.  
 
Statistical analysis 
Median follow up was ascertained by reverse censoring on death. The cumulative 
probabilities of LC, PFS, LRP and OS were calculated using the Kaplan-Meier method and 
were all defined from time of SBRT until the corresponding event or censored at date of last 
follow up. Wilcoxon signed rank test was used to assess change in EQ VAS scores over time. 
All analyses were performed using R studio.  
 
RESULTS 
30 patients, with 35 pelvic metastatic lesions, who met the pre-specified inclusion criteria, 
were included in the analysis. The median follow-up for the whole cohort was 24.5 months 
(IQR 17.8 – 28.8). Patient and treatment characteristics are summarised in Table 1. All 
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patients received the intended dose of 30Gy in 5 fractions and the OAR constraints were 
respected in all cases. Two examples plans are provided [Figure 1]. Approximately equal 
numbers were treated using Cyberknife (14) and VMAT linac (16). All patients had 
previously histologically confirmed adenocarcinoma of the rectum and had radical total 
mesorectal excision  of their pelvic primary. 97% (29/30) had neoadjuvant pelvic 
radiotherapy with 90% (27/30) receiving chemoradiation and two patients receiving short 
course radiotherapy. One patient  received 66Gy in 33 fractions for prostate bed and had an 
anterior resection alone for his rectal cancer. Serum PSA and PSMA PET scans testing ruled 
out prostate cancer recurrence. The interval between completing initial radiotherapy and 
SBRT re-irradiation was a median 41.9 months (range 11.3 – 90.4). 
 
The majority of patients had received prior chemotherapy, in either the adjuvant or metastatic 
setting, although 30% were chemotherapy naïve at the time of treatment and no 
chemotherapy was administered for the recurrence. Treated recurrences were located most 
frequently in the lateral compartments of the pelvis (71.4%) [Figure 2].     
  
The most common (73%) prior radiation dose was 45Gy in 25 fractions with concurrent 
capecitabine. The cumulative, median biologically effective doses (BED) with an alpha/beta 
ratio 5 and 10, along with cumulative equivalent dose in 2 Gray per fraction are shown in 
Table 2. No adjustment for recovery was made.  
 
Efficacy 
 
Using Kaplan-Meier estimates, the 1-year local control was 84.9% (95% CI 70.6 – 99) and a 
2-year local control of 69% (95% CI 51.8 – 91.9) [Figure 3A]. Locoregional control at 1 and 
2 years was 78% (95% CI 62.3 – 97.7) and 49% (95% CI 25.5 – 94.6), respectively [Figure 
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3B]. The median PFS was 12.1 months (95% 8.6 – 17.66) [Figure 3C ]. The median OS was 
28.3 months (95% CI 17.88 – 39.5 months) with a 1-year OS of 95.0% and a 2-year OS of 
84.4% [Figure 3D ].  
 
Quality of life outcomes 
 
Most patients were asymptomatic at presentation, with pain (28% G1/2) being the most 
common baseline symptom. Only one patient had baseline symptoms above CTCAE V4.0 
G2, with G3 diarrhoea. Acute toxicity data was available in 93% (28/30) of the cohort. The 
most reported acute toxicity was G1 fatigue (26.1%) and G2 diarrhoea (13%), with no acute 
toxicities greater than G2 [Table 2]. Late toxicity data was available for 80% of the cohort 
(24/30). One patient experienced G3 pain, possibly related to SBRT, which started 
approximately 15 months after completion of treatment,  12 months after distant relapse, and 
without clear evidence of local progression on serial imaging [Figure 4 ]. The most common 
late toxicity was G1 cystitis (10%). At the time of reporting, no patients had experienced 
symptomatic fractures of the pelvis, osteoradionecrosis or lymphedema which is encouraging 
given the large proportion of pelvic side wall disease treated. The median EQ-VAS score, at 
3 months post re-irradiation, improved from a median of 75 (range 40- 80) at baseline to 85 
(range 45-90) [Wilcoxon signed rank, p=0.009].  
DISCUSSION 
Although advances in the multimodality treatment of rectal cancer have reduced local 
recurrence, it remains a significant clinical challenge. Our cohort adds to the current literature 
in a number of important ways; it is the largest SBRT cohort to date, patients were treated 
within the last 5 years, we used a prospectively maintained database with clear patient criteria 
and standardised treatment delivery. We demonstrate that re-irradiation with 30Gy in 5 
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fractions is well tolerated and achieves excellent local control rates with limited toxicity. We 
also report on PROM which is entirely unique in this setting and absent from previous 
studies. 
 
The local control rates 84.9% and 69% at 1-year and 2-years respectively, compare 
favourably with previous reports of re-irradiation in LRRC. A recent meta-analysis estimated 
1 and 2-year LC of 72.0 % and 54.8% for patients treated with re-irradiation alone, and 
84.4% and 63.8% in patients who underwent re-irradiation plus surgery 10. The median OS 
was 28.3 months (95% CI 17.88 – 39.5 months) which again is superior to that seen in the 
previous reviews of re-irradiation alone in LRRC, although other SBRT series also recorded 
high LC and OS  17,19,25. Whether this is a genuine increase in effectiveness or a selection bias 
towards smaller, better prognosis tumours is unclear. In a cohort of presacral recurrences with 
a median tumour volume of 52.5cm, Heron et al 18 demonstrated 1 and 2 year LC of 90.9% 
and 68.2.% respectively with median dose prescription of 36Gy in 3 fractions. No G3 or G4 
toxicities were reported at a median follow up of 16.1 months. Dagoglu et al treated 18 
patients with a median dose of 25Gy in 5 fractions, achieved an estimated 1- and 2-year LC 
rate of 100% and 93.7% respectively with a median follow up of 38 months. Approximately 
60% of lesions were located in the pelvic side wall. Two G3 and one G4 toxicity were 
reported. Lastly, in the first SBRT series for LRRC reported, Kim et al demonstrated a 4 year 
local progression free survival rate of 74.3% for 23 patients treated with a median dose of 
39Gy in 3 fractions and reported one G4 toxicity 19.  Despite clear heterogeneity within and 
between these cohorts, SBRT achieves high LC rates with acceptable toxicity rates.  
 
Previous systematic reviews, which included SBRT studies, have demonstrated superior 
survival outcomes with surgery for LRRC, albeit at a higher risk of late toxicity 6,10.  All 
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patients in this cohort were assessed by a surgical service experienced in the management of 
LRRC prior to referral for SBRT. Location of recurrence is often the determining factor when 
assessing suitability for surgery with posterior or lateral tumours involving the sacral 
promontory, iliac vessels or pelvic wall often contraindications for surgical resection 7,26, 
although surgeons may disagree on the criteria for case selection. It is therefore unsurprising 
that 71.4 % (25/35) of the lesions treated in this series were located where surgery is often 
contraindicated. Alternatively, this lateral pelvic side wall disease may not been identified at 
the time of the primary treatment (radiation and surgery). Standard radiation approaches and 
TME are not always sufficient to prevent lateral lymph node recurrences in locally advanced 
lower rectal cancers, with a suggestion that lateral nodal dissection improves local recurrence 
rates 27. Primary diagnostic images were not available for clarification in the dataset. In our 
opinion, the most likely clinical scenario is that of a seeded, radioresistant, clonal metastases 
at the treated site. All the treated sites were reviewed for position within the previous 
radiations fields and found to be in the high dose areas. Whether the clone was present in the 
primary rectal tumour, or at the metastatic site, during the initial radiotherapy course is 
unknowable. Given that all patients were thoroughly re-staged prior to treatment, and found 
to have only 1-2 lesions, would argue against seeding of a radiosensitive metastases from 
outside the previous RT field.  
 
Several studies have sought to determine factors that may help identify which patients would 
be most likely to benefit from re-irradiation 13,19,25,28. Tumour location and size are the most 
associated with differing treatment outcomes. Axial and anterior tumours are associated with 
more toxicity following re-irradiation probably due to the increased dose to small bowel and 
bladder 29. In our cohort, 71.4% (25/35) of the targets were in the lateral pelvic compartments 
and could account for the low toxicity rates seen here. The importance of tumour size is less 
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clear in terms of influencing high-grade toxicity 19,22,30 with one study suggesting that 
tumours less than 3cm in size may have better long-term control 28. The median GTV volume 
in this cohort was 14.3cm3 (equivalent sphere 3cm), smaller than previous SBRT cohorts, 
which could have contributed to the excellent local rates and OS.  
 
The median OS is comparable to the median survival following R1 resection from the recent 
PelvEx Collaboration 31.  This suggests that unless the pre-operative likelihood of an R0 
resection is high that SBRT is potentially viable alternative, accepting that the presented 
cohort may have an inherent better prognosis due to small volume disease compared to some 
resected cohorts. Re-irradiation has the potential to delay the time to systemic treatment, 
provide local control and avoid unnecessary morbid surgeries for whom systemic disease 
becomes the life limiting issue. Surgeons may disagree on the ‘operability’ of some of the 
treated cases underlining the need for a consensus approach to LRRC. 
 
Concerns regarding re-irradiation have focused on the potential for severe toxicity. Older 
series of re-irradiation for LRRC demonstrated grade 3/4 acute toxicities rates of up to 35% 
11,12,32,33
. Clinical evidence dictating re-irradiation tolerances of the bladder, small bowel and 
other pelvic contents is lacking and no consensus dose constraints exist to date 34. Abusaris et 
al set cumulative constraints of <10cm3 small bowel to receive no more than 110Gy3 EQD2, 
<10cm3 bladder to receive no more than 120Gy3 EQD2 and, along with tight margins and 
high quality IGRT, demonstrated low toxicity rates 22. Others suggest subtracting the 
previous dose from the traditional constraint; or, where not possible, they suggest that a 
degree of repair of up to 50% could be assumed depending on the interval to re-irradiation 16. 
Using these approaches, we demonstrate a high local control rate with low late toxicity rates, 
with the majority (53%) reporting no acute toxicity and none greater than G2. The rapid dose 
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fall off generated by an SBRT means that point doses within 2cm of the PTV are the main 
limiting factors in target coverage [Figure 1c]. This in turn is governed by individual patient 
anatomy and site of recurrences.   
 
Proton radiation therapy (PRT) for re-irradiation has demonstrated significant dosimetric 
advantages over IMRT in LRRC, with reduced small bowel doses 35. However, out of 7 
patients 3 had acute G3 toxicity and 3 had late G4 toxicity. The overall re-irradiation mean 
PRT was 61.2Gy (RBE) and the mean CTV disease volume was also significant larger at 246 
cm3 which may have resulted in the increased toxicity. But these data underline that there is 
no ‘gold-standard’ radiation modality for re-irradiation with many patient and treatment 
related factors that need accounting for. Ultimately the goal for patients that are deemed 
inoperable is to achieve durable local control, minimal toxicity and sustained QoL. The 
optimal way to achieve that goal – SBRT, PRT, hyperfractionation – should be an active area 
of research. 
 
We have demonstrated a statistically significant improvement in patient reported QoL scores 
at 3 months using the EQ-5D VAS at the end of the acute toxicity phase. The exact 
mechanism by which patients would report feeling better from SBRT is unclear.  It is 
possible patients reported an improvement in a global health assessment scale because of the 
psychological benefit of ‘something being done’. However, it is clear that patients did not 
feel worse after the acute toxicity phase had resolved, which coupled with the low objective 
toxicity rates, suggests SBRT is well tolerated.  
 
This study is limited by the small numbers of patients included which, although the largest to 
date, limits firm conclusions being drawn. The inherent nature of a non-randomised study 
risks, selection bias and an over-estimation of the efficacy of treatment. These risks are 
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minimised by the a priori defined criteria for entry in the SBRT treatment program and the 
prospective nature of the data collection.   
 
In conclusion, our findings demonstrate that SBRT re-irradiation for patients who are non-
surgical candidates with small volume pelvic recurrence has minimal acute toxicity and 
offers the opportunity for local disease control and symptom control and improved QoL. We 
believe there is an imperative across the interested disciplines of radiation and surgical 
oncology to integrate existing knowledge and experience with a multi-disciplinary approach 
to a clinical trial, to ask the relevant questions in locally recurrent rectal cancer. 
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Figures Legend 
Figure 1. (A) 30Gy prescription dose colour wash of example case showing irradiation of 
bilateral pelvic nodal recurrences and resulting dose volume histogram (B) 30Gy prescription 
dose colour wash of single central recurrence and resulting dose volume histogram (C) 
Example of line profile of dose fall off from the edge of PTV showing rapid dose fall off to 
2cm distance. 
 
Figure 2. Distribution of targets within each pelvic compartment (N=35). Two additional 
targets in the inguinal region, which co-occurred with another treated area inside the pelvis, 
are not shown [reproduced on permission from Georgiou et al 21] 
 
Figure 3. Kaplan Meier estimates and associated risk tables of local control/in field 
progression (A) [N=35]; loco-regional control (B) [N=30]; progression free survival (C) and 
overall survival (D). Vertical dashed lines indicate median survival estimates 
 
Figure 4. Swimmer plot of each patient showing time to progression and whether they 
progressed locally (Local), locoregionally (LR), distant only (Distant), at multiple sites 
(Multiple) or had sustained local control (None). Development and grade of late toxicity is 
also shown 
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Table 1. Cohort characteristics 
 
 
 
 
  
*Other = Penile bulb 
Variable N = 30 % 
Age 65 
(Range 36-84) 
_ 
Gender   
Male 19 63 
Female 11 37 
ECOG   
0 23 77 
1 7 23 
Treated site   
Lymph Node 29 96 
Other* 1 4 
Median GTV 
(range) 
14.3 cm
3
  
(0.28 – 89.7) 
 
Median GTV 
equivalent 
diameter 
(range) 
3 cm 
(0.8 – 5.54) 
 
Prior 
chemotherapy 
  
Yes 21 70 
No 9 30 
Number of 
metastases 
  
1 25 83 
2 5 17 
Previous RT 
dose 
  
45Gy/25# 22 73.3 
50.4Gy/28# 4 13.3 
50Gy/25# 1 3.3 
66Gy/33# 1 3.3 
25Gy/5# 2 6.6 
Median 
Cumulative 
Dose  
(range) 
  
BED5  127.2  
(116 – 158.4) 
 
BED10 101.1  
(85.5 – 127.2) 
 
EQD2(α/β 10) 84.2  
(71.2 – 106) 
 
EQD2(α/β 3) 97.2  
(94 – 120) 
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Table 2. Acute and late toxicity reporting. Grading was as per Common Terminology Criteria 
for adverse events v4.0 
  
Toxicity Acute  
N (%) 
Late  
N (%) 
Grade 1 (All) 7 (23)  
Pain 2 (6) 1 (3) 
Fatigue 8 (26) - 
Proctitis 1 (3) - 
Cystitis 1 (3) 3 (10) 
Grade 2 (All) 5 (16)  
Pain 1 (3) - 
Cystitis 1 (3) - 
Diarrhea 4 (13) 2 (6) 
Grade 3 (All) -  
Pain - 1 (3) 
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